PTU - Polskie Towarzystwo Urologiczne
home page
current numbers
archival numbers
list of articles:
list przewodni/covering letter
editor
Scientific Committee
publisher
subscription
advertising
important links

Non-crystalline components of urinary stones
Article published in Urologia Polska 2003/56/1.

authors

Waldemar Różański 1, Leszek Klimek 2, Krzysztof Jakubowski 2, Eugeniusz Miękoś 1, Zbigniew Górkiewicz 2
1 Klinika Urologii i Rehabilitacji Urologicznej Instytutu Chirurgii Uniwersytetu Medycznego w Łodzi
Kierownik kliniki: prof, dr hab. Eugeniusz Miękoś
2 Instytut Inżynierii Materiałowej Politechniki Łódzkiej w Łodzi
Dyrektor instytutu: prof, dr hab. inż. Piotr Kula

keywords

urinary tract, urinary stone, urinary stone matrix, scanning electron microscop

summary

The last two decades were marked by an intense development of up-dated methods of urinary stone formation treatment. The majority of worldwide publications covers the issues connected with the technique and effects of applied treatment. With the intention of directing attention to other facets of urinary stone formation, we attempt to collect and display information about non-crystalline components of urinary stones and proteins that participate in the process of their formation in urinary tract.

references

  1. 1. Morse RM, ResnickMJ: Urinary stone matrix. JUrol 1988; ] 39: 602-605.
  2. 2. Koide T, Miyagawa M. Kinoshila K: Matrix stones. J Urol 1977:117: 786-787.
  3. 3. Allen TD. Spence MH: Matrix stones. J Urol 1966; 95: 284-290.
  4. 4. VarmaJS: Matrix calculus anuria. Brit JUrol 1987; 59:190-191.
  5. 5. Kim KM: Mulberry particles formed by red blood cells in human weddeli-te stones. JUrol 1983; 129:855-857.
  6. 6. Stapleton AMP, Ryall RL: Blood coagulation proteins and urolithiasis are linked: ctystal matrix protein is the F 1 activation peptide of human prothrombin. Brit J Urol 1995: 75: 712-719.
  7. 7. Petersen TK. Thogersen JDA. Petersen SE: Identification of hemoglobin and two serine proteases in acid extracts of calcium containing kidney sto-nesJUrol 1989:142:176-180.
  8. 8. Khan SR: Tubidar cell surface events during nephrolitluasis. Curr Opin Urol 1997; 7:240-247.
  9. 9. Khan SR: Interactions between stone forming calcific crystals and macro-molecules. Urol Int 1997: 59: 59-71.
  10. 10. Almani E Lacour B, Daudon M: Uronic-acid-rich protein: une novelle glycoprotein inhibitrice de la cristallisation de 1\\\'oxalate de calcium in vitro. Nephrol 1996; 17:157-162.
  11. 11. Tiselius HG: Macromolecidar substances - their role in urolithiasis. Curr Opin 1997: 7: 234-239.
  12. 12. Atmani F. Lacour B, Drueke T. Daudon M: Isolation and purification of a new glycoprotein from human urine inhibiting calcium oxalate crystallization. Urol Resea 1993; 21; 61-66.
  13. 13. Grover PK. Resnick MJ: Evidence for the presence of abnormal proteins in the urine ofrecurrent stone formers. JUrol 1995; 153:1716-1721.
  14. 14. Mustafi D. Nakagawa Y: Characterization ofCa2+ binding sites in the kidney stone inhibitor glycoprotein nephrocalcin using vanadyl ions: different matal binding properties in strong and weak inhibitor proteins reve-aledby EPRandENDOR. Kiachem 1996: 35:14703-14709.
  15. 15. Sorensen S, Justesen SJ. Johnsen AU: Identification of a macromolecu-lar crystal growth inhibitor in human urine ae steopontin. Urol Res 1995:23:327-334.
  16. 16. Gokhale JA, Glenlon PA. Khan SR: Locahaaion ofTamm-Horsfall protein and osteoponlbun rat nephrolitluasis model. Nephron 1996: 73: 456-461.
  17. 17. Nishio S, Hatanaka M, Takeda H. Iseda T. Iwata H. Yokoyama M: Analysis of urinary concentrations of calcium phosphate crystal - associated proteins: alfa-2-HS-glycoprotein prothrombin F 1 and osteopontin. J Am Soc Nephrol 1999; 10: 394-396.
  18. 18. Nishio S. Abe Y, Wakatsuki A. Iwata H, Ochi K, Takcuchi M. Matsu-moto A: Matrix glycosaminoglycan in urinary stones. J Urol 1985: 134: 503-506.
  19. 19. Iwata H, Kamei O. Abe Y. Nishio S. Wakatsuki A. Ochi K Takeuclii M: The organic matrix of urinary uric acid crystals. J Urol 1988:139: 607-610.
  20. 20. Sarica K, Turkolmez K. Kupeli B, Akpoyraz M. Durak I, Kupeli S, Ko-sar A: Glycosaminoglycan content of Ca-oxtdate stone matrix. Urol Int 1997:58:43-46.
  21. 21. Cerini C. Geider S. Dussol B, Hennequin C, Daudon M, Veesler S, Nit-sche S. oistelle R, Berlhezene P. Dupuy P, Ań A, Beiiand Y, Dragom J. C, Verdier JM: Nucleation of calcium oxalate crystals by albumin: involvement in the prevention of stone formation. Kid Internal 1999: 55: 1776-1786.
  22. 22. Tsujihata M. Miyake 0. Yoshimura K. Kakimoto KI, Takahara S. Okuyama A: Fibronectin as a potent inhibitor of calcium oxalate urolithiasis. JUrol 2000:164:1718-1723.

correspondence

Waldemar Różańskt
Klinika Urologii i Rehabilitacji Urologiczne! Uniwersyteckiego Szpitala
Klinicznego Nr 2 int. Wojskowej Akademii Medycznej
ul. Żeromskiego 113
90-549 Łódź